QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: A case report and review of the literature

Cardiology Journal

Volumn 19, Issue 4, 2012, Pages 434-438

  Lynch, Donald R ^a   Washam, Jeffrey B ^b   Newby, L Kristin ^c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

QTc prolongation; Torsades de pointes; Vorinostat (Zolinza)

Indexed keywords

CREATININE; D DIMER; DOXEPIN; GLUCOSE; HEMOGLOBIN; MAGNESIUM; POTASSIUM; SERTRALINE; VORINOSTAT;

ADULT; ARTICLE; BEDTIME DOSAGE; CASE REPORT; CLINICAL FEATURE; CREATININE BLOOD LEVEL; CUTANEOUS T CELL LYMPHOMA; HUMAN; HYPOKALEMIA; LOW DRUG DOSE; MALE; MEDICAL HISTORY; POLYMORPHIC VENTRICULAR TACHYCARDIA; QRS COMPLEX; QT PROLONGATION; RESUSCITATION; SINUS RHYTHM; SUPPLEMENTATION; T WAVE INVERSION; THROMBOCYTE COUNT; TORSADE DES POINTES; UREA NITROGEN BLOOD LEVEL;

EID: 84864069212     PISSN: 18975593     EISSN: None     Source Type: Journal    
DOI: 10.5603-CJ.2012.0078     Document Type: Article

References (14)

1. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA, 2002; 287: 2215-2220.
2. Gupt A, Lawrence AT, Krishnan K, Kavinsky CJ, Trohman RG. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsades de pointes. Am Heart J, 2007; 153: 891-899.
3. Mehnert JM, Kelly WK. Histone deacetylase inhibitors: Biology and mechanism of action. Cancer J, 2007; 13: 23-29.
4. Kelly WK, Richon VM, O'Connor O et al. Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res, 2003; 9: 3578-3588.
5. Kelly WK, O'Connor OA, Krug LM et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol, 2005; 23: 3923-3931.
6. Duvic M, Talpur R, Ni X et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood, 2007; 109: 31-39.
7. Olsen EA, Kim YH, Kuzel TM et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol, 2007; 25: 3109-3115.
8. Baker B, Dorian P, Sandor P et al. Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. J Clin Psychopharmacol, 1997; 17: 15-21.
9. Alter P, Tontsch D, Grimm W. Doxepin-induced torsades de pointes tachycardia. Ann Intern Med, 2001; 135: 384-385.
10. Strasberg B, Coelho A, Welch W, Swiryn S, Bauernfeind R, Rosen K. Doxepin induced torsades de pointes. Pacing Clin Electrophysiol, 1982; 5: 873-877.
11. Isbister GK, Bowe SJ, Dawson A, Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol, 2004; 42: 277-285.
12. de Boer RA, van Dijk TH, Holman ND, van Melle JP. QT interval prolongation after sertraline overdose: A case report. BMC Emerg Med, 2005; 5: 5.
13. Kannankeril PJ, Roden DM. Drug-induced long QT and torsades de pointes: Recent advances. Curr Opin Cardiol, 2007; 22: 39-43.
14. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther, 1981; 30: 239-245.